-
Merck's 2023 revenue exceeded 60 billion US dollars, and K-drug topped the list of "drug kings"
On February 1st, MSD announced its 2023 performance. The company achieved a revenue of 60.115 billion US dollars throughout the year, a year-on-year increase of 1%; After deducting the influence of C ... -
Annual sales of 25 billion US dollars. Merck's "K-drug" dominates the global "drug king"
On February 1st, multinational pharmaceutical company MSD's 2023 annual report showed that its PD-1 monoclonal antibody Keytruda (hereinafter referred to as K-drug) has become the new global "drug ki ... -
Sales Competition of Heavyweight Drugs: K-drug Becomes the Global New Drug King, and Megglutide is Stepping Ahead
Recently, with the release of 2023 financial reports by multinational pharmaceutical companies such as Merck, Pfizer, Abbott Laboratories, and GlaxoSmithKline (GSK), sales performance of some heavywe ... -
Global "Medicine King" Competition Upgrades: Smegglutide vs K-drug Tilposide, Stepping Forward
Entering 2024, major multinational pharmaceutical companies (MNCs) have successively released their financial reports for the previous year, and the dust has settled on the global "drug king" competi ...